New combo therapy aims to calm nerve pain in rare blood conditions
NCT ID NCT05065554
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This study tests whether combining acalabrutinib with rituximab (a standard antibody treatment) is safe and effective for people with nerve damage linked to two blood disorders: IgM MGUS and Waldenstrom macroglobulinemia. The goal is to reduce abnormal IgM protein levels, which can cause numbness, tingling, and weakness. The trial enrolled 12 adults and is no longer recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROPATHY;PERIPHERAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.